320 related articles for article (PubMed ID: 34520432)
1. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
2. Epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
[TBL] [Abstract][Full Text] [Related]
4. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Valenza C; Trapani D; Gandini S; Sposetti C; Boscolo Bielo L; Marra A; Giarratano T; Favero D; Cortesi L; Moscetti L; Pistelli M; Berardi R; Zambelli A; Lambertini M; Del Mastro L; Guarneri V; Vernieri C; Curigliano G
Eur J Cancer; 2023 Sep; 190():112944. PubMed ID: 37437366
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Moss HA; Perhanidis JA; Havrilesky LJ; Secord AA
Gynecol Oncol; 2021 Oct; 163(1):50-56. PubMed ID: 34301411
[TBL] [Abstract][Full Text] [Related]
10. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
12. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
[TBL] [Abstract][Full Text] [Related]
13. Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
Lee B; Chang SJ; Kwon BS; Son JH; Lim MC; Kim YH; Lee SW; Choi CH; Eoh KJ; Lee JY; Suh DH; Kim YB
PLoS One; 2023; 18(11):e0294647. PubMed ID: 37976295
[TBL] [Abstract][Full Text] [Related]
14. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
Yuan H; Li N; Wu L; Yao H
J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
[TBL] [Abstract][Full Text] [Related]
15. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
16. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
17. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
[TBL] [Abstract][Full Text] [Related]
18. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
19. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
[TBL] [Abstract][Full Text] [Related]
20. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
